<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 26, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6263926/global-mrna-cancer-vaccines-market-opportunity?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=hm8mv5&amp;utm_campaign=2338033+-+Global+mRNA+Cancer+Vaccines+Market+Report+2026-2031%3a+Assesses+More+Than+70+Vaccines+Through+Phase+III&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Global mRNA Cancer Vaccines Market Opportunity, Therapeutic Development Proprietary Technologies &amp; Clinical Trials Insight 2026">"Global mRNA Cancer Vaccines Market Opportunity, Therapeutic Development Proprietary Technologies &amp; Clinical Trials Insight 2026"</a> has been added to ResearchAndMarkets.com's offering. The global mRNA cancer vaccines market is advancing rapidly, supported by innovation in mRNA sequence design, lipid nanoparticle delivery, neoantigen identification, and precision oncology. Early clinical findings indicate that mRNA-based cancer vaccines may support scalable and highly targeted treatment strategies, particularly when integrated with established immuno-oncology therapies. Report Findings and Highlights: <ul><li>Global mRNA cancer vaccines market trends by region and therapeutic indication</li><li>First commercial availability of an mRNA cancer vaccine projected by 2031</li><li>Analysis of more than 70 mRNA cancer vaccines in clinical development</li><li>Phase III identified as the highest stage of clinical development</li><li>Key clinical development timelines and anticipated milestones</li><li>Clinical trials analysis by company, country, indication, and development phase</li><li>Assessment of more than 10 proprietary mRNA vaccine technology platforms</li><li>Competitive landscape, partnerships, and commercial opportunities</li></ul> Despite significant progress, the sector remains at an early stage of commercialization. Many mRNA cancer vaccine candidates are in preclinical development or early clinical trials, while the most advanced programs have reached Phase III. Although several studies have reported encouraging immunogenicity, safety, and efficacy signals, additional evidence is required to establish durable survival benefits across multiple cancer indications. This report provides investors, pharmaceutical companies, biotechnology developers, research organizations, and other stakeholders with a structured assessment of the global mRNA cancer vaccines market. It examines the clinical pipeline, competitive environment, proprietary technologies, development partnerships, and potential commercial opportunities across major oncology indications. mRNA Cancer Vaccine Clinical Trials Analysis The report evaluates mRNA cancer vaccine development across preclinical research, early-stage human studies, mid-stage trials, registration-oriented Phase III programs, and studies assessing established candidates in new treatment settings. The clinical pipeline covers high-incidence tumors and rare cancers, demonstrating the expanding role of mRNA technology within cancer immunotherapy. Clinical programs are assessed according to treatment strategy, therapeutic indication, line of therapy, route of administration, trial design, sponsor, and development collaboration. The analysis also reviews reported safety and efficacy measures, including objective response rate, progression-free survival, immune response durability, and other relevant clinical outcomes. Particular attention is given to combination strategies involving immune checkpoint inhibitors and other anticancer agents. These approaches are being investigated across solid tumors such as melanoma, non-small cell lung cancer, gastric cancer, breast cancer, colorectal cancer, and head and neck cancer. The report also highlights key clinical timelines, development milestones, and factors likely to influence regulatory progress. Leading Companies in mRNA Cancer Vaccine Research and Development The competitive landscape includes major pharmaceutical companies and specialist biotechnology businesses with capabilities in RNA engineering, immuno-oncology, antigen discovery, and advanced drug delivery. BioNTech and Moderna are among the leading developers of personalized neoantigen vaccines for solid tumors, supported by established mRNA platforms and strategic clinical collaborations. Other companies, including CureVac, pHion Therapeutics, and Immorna, are expanding pipelines through innovations designed to improve RNA stability, delivery performance, antigen expression, and immune activation. Industry participants are developing both personalized and off-the-shelf mRNA cancer vaccines while pursuing licensing agreements, research partnerships, co-development programs, and investment opportunities. Proprietary mRNA Cancer Vaccine Technology Platforms Proprietary technology platforms are central to the development and manufacturing of mRNA cancer vaccines. The report evaluates more than 10 platforms incorporating computational antigen design, sequence and codon optimization, untranslated region engineering, lipid nanoparticle delivery, and manufacturing capabilities. Modular platform strategies may help developers accelerate candidate selection, combine multiple tumor targets, improve product consistency, and reduce development risk. Innovac Therapeutics is one example of a company using an integrated system that combines computational sequence design, codon and untranslated region optimization, and lipid nanoparticle-based delivery. Its platform supports the development of candidates intended to activate CD4+ and CD8+ T-cell responses. INV002 is among the programs being developed through this approach, using proprietary sequence-design tools and delivery technology intended to protect mRNA from degradation. Future Outlook for the Global mRNA Cancer Vaccines Market Future market opportunities are expected to extend beyond melanoma into non-small cell lung cancer, colorectal cancer, breast cancer, gastric cancer, and other gastrointestinal tumors. As clinical evidence matures, mRNA cancer vaccines may gain greater relevance in adjuvant and minimal residual disease settings, where early immune intervention could support more durable outcomes. Biomarker-driven patient selection, neoantigen identification, and tumor mutation burden assessment are expected to strengthen target selection and improve clinical trial design. Artificial intelligence-based neoantigen prediction may further increase development efficiency and help optimize personalized vaccine candidates. Although commercial adoption has not yet begun, advancing clinical pipelines, expanding combination-treatment strategies, proprietary platform innovation, and increasing regulatory engagement support a multi-stage growth outlook. The report positions the mRNA cancer vaccines market as an emerging oncology opportunity with significant potential for therapeutic development, strategic partnerships, and long-term investment through 2031 and beyond. Key Topics Covered 1. Research Methodology 2. mRNA Vaccines as Next Generation Cancer Immunotherapy 2.1 mRNA Vaccines Overview 2.2 mRNA Vaccines vs Other Cancer Therapeutic Approaches 2.3 mRNA Vaccines vs Other Vaccines 3. Global mRNA Cancer Vaccines Market Overview 3.1 Current Market Trends 3.2 Future Market Opportunities 4. Global Cancer mRNA Vaccines Clinical Trails Overview 4.1 By Phase 4.2 By Company 4.3 By Country 4.4 By Indication 5. Global mRNA Cancer Vaccine Clinical Trials Insight by Company, Country, Indication &amp; Phase 5.1 Research 5.2 Preclinical 5.3 Phase I 5.4 Phase I/II 5.5 Phase II 5.6 Phase II/III 5.7 Phase III 6. Global mRNA Cancer Vaccines Clinical Landscape by Indication 6.1 Breast Cancer 6.2 Brain Cancers 6.3 Melanoma 6.4 Head &amp; Neck Cancers 6.5 Cervical Cancer 6.6 Lung Cancer 6.7 Gastrointestinal Cancers 7. Global mRNA Cancer Vaccines Market Trends by Country 7.1 US 7.2 Russia 7.3 China 7.4 Australia 7.5 Europe 7.6 Canada 7.7 UK 8. Proprietary Technologies &amp; Methodologies for mRNA Cancer Vaccine Development 9. Competitive Landscape 9.1 BioNTech 9.2 Combined Therapeutics 9.3 CureVac 9.4 EpiVax 9.5 HDT Bio 9.6 Immorna 9.7 Immune Design 9.8 MDimune 9.9 Moderna Therapeutics 9.10 NeoCura 9.11 pHion Therapeutics 9.12 Providence Therapeutics 9.13 RinuaGene 9.14 RNAimmune 9.15 TransCode Therapeutics For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6263926/global-mrna-cancer-vaccines-market-opportunity?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=hm8mv5&amp;utm_campaign=2338033+-+Global+mRNA+Cancer+Vaccines+Market+Report+2026-2031%3a+Assesses+More+Than+70+Vaccines+Through+Phase+III&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/i9ll4d</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZDI2NzM0YWItN2JiMS00MzcwLWI3ZWEtODY3NzRjMmExMGFiLTEwMjY3MzctMjAyNi0wOC0yNi1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Global mRNA Cancer Vaccines Market Report 2026-2031: Assesses More Than 70 Vaccines Through Phase III

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn